Envista (NVST) Q3 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Earnings

Envista Holdings posted a convincing beat across the board in the third quarter of fiscal 2025, with adjusted diluted EPS of $0.32 clearing the $0.28 consensus estimate by 15.94% and revenue of $669.90 million topping expectations by 4.55% on 11.5% y… Read more Envista Holdings posted a convincing beat across the board in the third quarter of fiscal 2025, with adjusted diluted EPS of $0.32 clearing the $0.28 consensus estimate by 15.94% and revenue of $669.90 million topping expectations by 4.55% on 11.5% year-over-year growth. The primary engine behind the quarter's strength was the Specialty Products & Technologies segment, which grew total sales 13.0% to $431.50 million, while Equipment & Consumables contributed 8.7% growth to $238.40 million, together reflecting broad-based momentum across the dental portfolio. Profitability expanded sharply, with adjusted EBITDA rising 77% to $97.10 million and adjusted EBITDA margin widening 540 basis points to 14.5%. A GAAP net loss of $30.30 million, driven by a $61.20 million discrete tax charge from intercompany loan restructuring, obscured the underlying operating progress. Management responded to the quarter's performance by raising full-year core sales growth guidance to approximately 4% and tightening adjusted diluted EPS guidance to $1.10 to $1.15, though some analysts flag potential headwinds from China's next round of volume-based procurement into 2026.